The identification of predictors of response to antiCGRP mAbs could favor tailored therapies and personalized treatment plans. This study is aimed at investigating predictors of ≥ 50%, ≥ 75% and 100% response at 24 weeks in patients with high-frequency episodic (HFEM: 8-14 days/month) or chronic migraine (CM).
Predictors of response to anti-CGRP monoclonal antibodies: a 24-week, multicenter, prospective study on 864 migraine patients / Barbanti, P., Egeo, G., Aurilia, C., Altamura, C., D'Onofrio, F., Finocchi, C., Albanese, M., Aguggia, M., Rao, R., Zucco, M., Frediani, F., Filippi, M., Messina, R., Cevoli, S., Carnevale, A., Fiorentini, G., Messina, S., Bono, F., Torelli, P., Proietti, S., et al.. - In: THE JOURNAL OF HEADACHE AND PAIN. - ISSN 1129-2369. - 23:1(2022), pp. 1-12. [10.1186/s10194-022-01498-6]
Predictors of response to anti-CGRP monoclonal antibodies: a 24-week, multicenter, prospective study on 864 migraine patients
Filippi, Massimo;Messina, Roberta;
2022-01-01
Abstract
The identification of predictors of response to antiCGRP mAbs could favor tailored therapies and personalized treatment plans. This study is aimed at investigating predictors of ≥ 50%, ≥ 75% and 100% response at 24 weeks in patients with high-frequency episodic (HFEM: 8-14 days/month) or chronic migraine (CM).| File | Dimensione | Formato | |
|---|---|---|---|
|
J Headache Pain 23_138.pdf
accesso aperto
Tipologia:
PDF editoriale (versione pubblicata dall'editore)
Licenza:
Creative commons
Dimensione
926.16 kB
Formato
Adobe PDF
|
926.16 kB | Adobe PDF | Visualizza/Apri |
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
